Qi Jianping, Zhuang Jie, Lu Yi, Dong Xiaochun, Zhao Weili, Wu Wei
School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery of MOE and PLA, Shanghai, China.
School of Pharmacy, Shanghai University of Medicine & Health Sciences, Shanghai, China.
Drug Discov Today. 2017 Jan;22(1):166-172. doi: 10.1016/j.drudis.2016.09.024. Epub 2016 Oct 3.
The in vivo fate of lipid-based nanoparticles (LBNs) is essentially determined by the properties of their lipid compositions. LBNs are rapidly degraded via lipolysis wherever lipases are abundant, especially in the gastrointestinal tract. LBNs that survive lipolysis can be translocated through the circulation to reach terminal organs or tissues. Lipid composition, particle size, and surface decoration, as well as the formation of protein corona, are the main factors influencing the in vivo fate of LBNs. As we discuss here, elucidation of the in vivo fate of LBNs helps weigh the balance between lipolysis and biorecognition, and is emerging as a new field of research.
基于脂质的纳米颗粒（LBNs）在体内的命运基本上由其脂质成分的性质决定。无论脂肪酶丰富在哪里，尤其是在胃肠道，LBNs都会通过脂解作用迅速降解。在脂解作用中存活下来的LBNs可以通过循环转运到达终末器官或组织。脂质组成、颗粒大小、表面修饰以及蛋白质冠的形成是影响LBNs体内命运的主要因素。正如我们在此所讨论的，阐明LBNs的体内命运有助于权衡脂解作用和生物识别之间的平衡，并且正在成为一个新的研究领域。
